Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-612 heterologous booster in AstraZeneca-vaccinated adults
NCT05167253Phase 1Withdrawn
- Sponsor
- United Biomedical, Inc.
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label, single-arm trial of UB-612 in coronavirus disease 2019 (COVID-19), sponsored by United Biomedical, Inc. Primary endpoints: Safety and tolerability and Immunogenicity. Planned start Feb 2022; status: withdrawn.
02
Drugs
UB-612
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05167253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167253.